Balaji
@bajji.bsky.social
Aspiring scientist -- Postdoc in Misha Beltran's lab @DanaFarber -- Tweets are mostly fictional :)
I really enjoyed co-mentoring Arianny Mordan this summer, a talented student from the Workforce Development Program
@danafarber.bsky.social. She gifted me a mug, but I’m too embarrassed to use it!
Excited to see all you’ll accomplish, Arianny!
Thanks to @mishabeltran.bsky.social for the support.
@danafarber.bsky.social. She gifted me a mug, but I’m too embarrassed to use it!
Excited to see all you’ll accomplish, Arianny!
Thanks to @mishabeltran.bsky.social for the support.
September 23, 2025 at 3:36 PM
I really enjoyed co-mentoring Arianny Mordan this summer, a talented student from the Workforce Development Program
@danafarber.bsky.social. She gifted me a mug, but I’m too embarrassed to use it!
Excited to see all you’ll accomplish, Arianny!
Thanks to @mishabeltran.bsky.social for the support.
@danafarber.bsky.social. She gifted me a mug, but I’m too embarrassed to use it!
Excited to see all you’ll accomplish, Arianny!
Thanks to @mishabeltran.bsky.social for the support.
Excited to share our new study in 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝!
We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target.
Huge thanks to @mishabeltran.bsky.social for her mentorship!
bit.ly/3HRIvAU
@aacrjournals.bsky.social
We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target.
Huge thanks to @mishabeltran.bsky.social for her mentorship!
bit.ly/3HRIvAU
@aacrjournals.bsky.social
Epigenetic De-repression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Abstract. Histologic transformation of prostate cancer from adenocarcinoma to neuroendocrine prostate cancer (NEPC) is associated with aggressive disease and poor prognosis. This lineage transition is...
bit.ly
August 26, 2025 at 6:57 PM
Excited to share our new study in 𝘾𝙖𝙣𝙘𝙚𝙧 𝙍𝙚𝙨𝙚𝙖𝙧𝙘𝙝!
We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target.
Huge thanks to @mishabeltran.bsky.social for her mentorship!
bit.ly/3HRIvAU
@aacrjournals.bsky.social
We focus on PROX1 as a key driver of neuroendocrine #ProstateCancer and highlight its potential as a therapeutic target.
Huge thanks to @mishabeltran.bsky.social for her mentorship!
bit.ly/3HRIvAU
@aacrjournals.bsky.social
Thank you for highlighting our recent work published in Cancer Research @aacrjournals.bsky.social!
@mishabeltran.bsky.social
@mishabeltran.bsky.social
Some prostate cancers evade therapy by transforming into aggressive neuroendocrine prostate cancer. New research highlights PROX1 as a key driver of this transformation and tumor growth, offering a potential treatment target.
➡️ bit.ly/4lEFHoD
➡️ bit.ly/4lEFHoD
August 22, 2025 at 3:15 PM
Thank you for highlighting our recent work published in Cancer Research @aacrjournals.bsky.social!
@mishabeltran.bsky.social
@mishabeltran.bsky.social
Honored to give 2 talks last week at the Gordon: Hormone-Dependent Cancers!
Huge thanks to organizers for the invitation.
Special thanks to my mentor, @mishabeltran.bsky.social, for her incredible support.
Loved learning, sharing ideas, and feeling the warmth of this amazing #GRC community.
Huge thanks to organizers for the invitation.
Special thanks to my mentor, @mishabeltran.bsky.social, for her incredible support.
Loved learning, sharing ideas, and feeling the warmth of this amazing #GRC community.
August 20, 2025 at 3:10 PM
Honored to give 2 talks last week at the Gordon: Hormone-Dependent Cancers!
Huge thanks to organizers for the invitation.
Special thanks to my mentor, @mishabeltran.bsky.social, for her incredible support.
Loved learning, sharing ideas, and feeling the warmth of this amazing #GRC community.
Huge thanks to organizers for the invitation.
Special thanks to my mentor, @mishabeltran.bsky.social, for her incredible support.
Loved learning, sharing ideas, and feeling the warmth of this amazing #GRC community.
Big thanks to Johann de Bono and @mishabeltran.bsky.social for the chance to contribute to a timely review on Cell Surface Targets in #ProstateCancer, now out in @natrevurol.bsky.social!
Had a wonderful time learning and collaborating with Cristina Boixareu Fiol and Tarek Taha.
bit.ly/42cCWTX
Had a wonderful time learning and collaborating with Cristina Boixareu Fiol and Tarek Taha.
bit.ly/42cCWTX
Targeting the tumour cell surface in advanced prostate cancer - Nature Reviews Urology
This Review provides an overview of the main targetable surface proteins in prostate cancer, defined as the surfaceome, discussing the mechanisms of action and efficacy of currently available drugs ta...
bit.ly
April 2, 2025 at 4:29 PM
Big thanks to Johann de Bono and @mishabeltran.bsky.social for the chance to contribute to a timely review on Cell Surface Targets in #ProstateCancer, now out in @natrevurol.bsky.social!
Had a wonderful time learning and collaborating with Cristina Boixareu Fiol and Tarek Taha.
bit.ly/42cCWTX
Had a wonderful time learning and collaborating with Cristina Boixareu Fiol and Tarek Taha.
bit.ly/42cCWTX
I am grateful to UroToday+GUOncToday for hosting me on their digital platform. It was a wonderful opportunity to share insights on our recent publication about EZH2 activity in advanced #ProstateCancer subtypes. Thank you for the support!
#BeltranLab
bit.ly/418kjQe
#BeltranLab
bit.ly/418kjQe
Lineage-Specific EZH2 Activity in Advanced Prostate Cancer Subtypes - Varadha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan joins Andrea Miyahira to discuss research examining EZH2's lineage-specific activity in advanced prostate cancer subtypes. His work explores how this histone modifier fu...
bit.ly
February 19, 2025 at 4:20 PM
I am grateful to UroToday+GUOncToday for hosting me on their digital platform. It was a wonderful opportunity to share insights on our recent publication about EZH2 activity in advanced #ProstateCancer subtypes. Thank you for the support!
#BeltranLab
bit.ly/418kjQe
#BeltranLab
bit.ly/418kjQe